S K Malin1, A Samat2, K Wolski3, B Abood2, C E Pothier3, D L Bhatt4, S Nissen3, S A Brethauer5, P R Schauer5, J P Kirwan6, S R Kashyap7. 1. 1] Department of Pathobiology, Cleveland Clinic, Cleveland, OH, USA [2] Department of Nutrition, Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA. 2. Department of Endocrinology, Cleveland Clinic, Cleveland, OH, USA. 3. Department of Heart and Vascular, Cleveland Clinic, Cleveland, OH, USA. 4. Veterans Affairs Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. 5. 1] Department of Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, OH, USA [2] Metabolic Translational Research Center, Endocrine and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA. 6. 1] Department of Pathobiology, Cleveland Clinic, Cleveland, OH, USA [2] Department of Nutrition, Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA [3] Metabolic Translational Research Center, Endocrine and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA. 7. 1] Department of Endocrinology, Cleveland Clinic, Cleveland, OH, USA [2] Metabolic Translational Research Center, Endocrine and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract
OBJECTIVE:Roux-en-Y gastric bypass (RYGB) produces more durable glycemic control than sleeve gastrectomy (SG) or intensive medical therapy (IMT). However, the contribution of acylated ghrelin (AG), a gluco-regulatory/appetite hormone, to improve glucose metabolism and body composition in patients with type 2 diabetes (T2D) following RYGB is unknown. DESIGN: STAMPEDE (Surgical Treatment and Medication Potentially Eradicate Diabetes Efficiently) was a prospective, randomized controlled trial. SUBJECTS:Fifty-three (body mass index: 36±3 kg m(-2), age: 49±9 years) poorly controlled patients with T2D (HbA1c (glycated hemoglobin): 9.7±2%) were randomized to IMT, IMT+RYGB or IMT+SG and underwent a mixed-meal tolerance test at baseline, 12, and 24 months for evaluation of AG suppression (postprandial minus fasting) and beta-cell function (oral disposition index; glucose-stimulated insulin secretion × Matsuda index). Total/android body fat (dual-energy X-ray absorptiometry) was also assessed. RESULTS: RYGB and SG reduced body fat comparably (15-23 kg) at 12 and 24 months, whereas IMT had no effect. Beta-cell function increased 5.8-fold in RYGB and was greater than IMT at 24 months (P<0.001). However, there was no difference in insulin secretion between SG vs IMT at 24 months (P=0.32). Fasting AG was reduced fourfold following SG (P<0.01) and did not change with RYGB or IMT at 24 months. AG suppression improved more following RYGB than SG or IMT at 24 months (P=0.01 vs SG, P=0.07 vs IMT). At 24 months, AG suppression was associated with increased postprandial glucagon-like peptide-1 (r=-0.32, P<0.02) and decreased android fat (r=0.38; P<0.006). CONCLUSIONS:Enhanced AG suppression persists for up to 2 years after RYGB, and this effect is associated with decreased android obesity and improved insulin secretion. Together, these findings suggest that AG suppression is partly responsible for the improved glucose control after RYGB surgery.
RCT Entities:
OBJECTIVE: Roux-en-Y gastric bypass (RYGB) produces more durable glycemic control than sleeve gastrectomy (SG) or intensive medical therapy (IMT). However, the contribution of acylated ghrelin (AG), a gluco-regulatory/appetite hormone, to improve glucose metabolism and body composition in patients with type 2 diabetes (T2D) following RYGB is unknown. DESIGN: STAMPEDE (Surgical Treatment and Medication Potentially Eradicate Diabetes Efficiently) was a prospective, randomized controlled trial. SUBJECTS: Fifty-three (body mass index: 36±3 kg m(-2), age: 49±9 years) poorly controlled patients with T2D (HbA1c (glycated hemoglobin): 9.7±2%) were randomized to IMT, IMT+RYGB or IMT+SG and underwent a mixed-meal tolerance test at baseline, 12, and 24 months for evaluation of AG suppression (postprandial minus fasting) and beta-cell function (oral disposition index; glucose-stimulated insulin secretion × Matsuda index). Total/android body fat (dual-energy X-ray absorptiometry) was also assessed. RESULTS: RYGB and SG reduced body fat comparably (15-23 kg) at 12 and 24 months, whereas IMT had no effect. Beta-cell function increased 5.8-fold in RYGB and was greater than IMT at 24 months (P<0.001). However, there was no difference in insulin secretion between SG vs IMT at 24 months (P=0.32). Fasting AG was reduced fourfold following SG (P<0.01) and did not change with RYGB or IMT at 24 months. AG suppression improved more following RYGB than SG or IMT at 24 months (P=0.01 vs SG, P=0.07 vs IMT). At 24 months, AG suppression was associated with increased postprandial glucagon-like peptide-1 (r=-0.32, P<0.02) and decreased android fat (r=0.38; P<0.006). CONCLUSIONS: Enhanced AG suppression persists for up to 2 years after RYGB, and this effect is associated with decreased android obesity and improved insulin secretion. Together, these findings suggest that AG suppression is partly responsible for the improved glucose control after RYGB surgery.
Authors: C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad Journal: Diabetologia Date: 2012-04-27 Impact factor: 10.122
Authors: Philip R Schauer; Sangeeta R Kashyap; Kathy Wolski; Stacy A Brethauer; John P Kirwan; Claire E Pothier; Susan Thomas; Beth Abood; Steven E Nissen; Deepak L Bhatt Journal: N Engl J Med Date: 2012-03-26 Impact factor: 91.245
Authors: Edward W Gregg; Haiying Chen; Lynne E Wagenknecht; Jeanne M Clark; Linda M Delahanty; John Bantle; Henry J Pownall; Karen C Johnson; Monika M Safford; Abbas E Kitabchi; F Xavier Pi-Sunyer; Rena R Wing; Alain G Bertoni Journal: JAMA Date: 2012-12-19 Impact factor: 56.272
Authors: Emily M Heiston; Natalie Z M Eichner; Nicole M Gilbertson; Julian M Gaitán; Sibylle Kranz; Arthur Weltman; Steven K Malin Journal: J Appl Physiol (1985) Date: 2019-01-10
Authors: Robyn A Tamboli; Reem M Sidani; Anna E Garcia; Joseph Antoun; James M Isbell; Vance L Albaugh; Naji N Abumrad Journal: Am J Physiol Endocrinol Metab Date: 2016-06-07 Impact factor: 4.310
Authors: J Hunter Mehaffey; Rachel L Mehaffey; Mathew G Mullen; Florence E Turrentine; Steven K Malin; Bruce Schirmer; Andrew M Wolf; Peter T Hallowell Journal: Obes Surg Date: 2017-05 Impact factor: 4.129